微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 57.67% | -10.98% | -4.14% | 62/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 60.16% | -2.83% | -2.51% | 50/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 61.71% | -1.53% | -2.55% | 47/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 63.32% | 2.12% | -2.25% | 41/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 64.78% | 8.44% | 4.63% | 38/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 61.91% | 2.46% | -1.2% | 48/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 62.66% | 6.28% | 1.06% | 45/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 62.01% | 3.11% | 3.8% | 46/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 59.74% | 1.46% | -1.14% | 51/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 60.42% | -3.11% | 2.48% | 52/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 58.96% | -3.95% | -1.95% | 59/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 60.13% | -2.99% | 2.14% | 57/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 58.87% | -4.49% | -5.59% | 57/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 62.36% | 3.93% | 1.59% | 54/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 61.39% | 0.19% | -0.97% | 53/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 61.99% | 1.39% | 0.56% | 53/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 61.64% | -2.05% | 2.73% | 51/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 60% | -5.85% | -2.07% | 64/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 61.27% | -3.97% | 0.21% | 51/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 61.14% | -2.14% | -2.85% | 54/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 62.93% | 4.68% | -1.25% | 42/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 63.73% | 5.28% | -0.12% | 52/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 63.8% | 7.51% | 2.12% | 46/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 62.48% | 6.45% | 3.93% | 47/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 60.12% | 5.72% | -0.69% | 46/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 60.54% | 1.31% | 2.01% | 56/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 59.34% | -1.63% | 1.11% | 50/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 58.7% | 1% | 3.22% | 53/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 56.86% | 4.12% | -4.83% | 47/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 59.75% | 6.77% | -0.96% | 53/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 60.33% | 9.27% | 3.81% | 39/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 58.11% | 7.56% | 6.41% | 43/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 54.62% | 7.03% | -2.41% | 49/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 55.96% | 12.27% | 1.36% | 54/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 55.21% | 15.68% | 2.19% | 38/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 54.03% | 17.81% | 5.88% | 38/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 51.03% | 11.38% | 2.37% | 38/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 49.85% | 1.28% | 4.44% | 50/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 47.73% | 2.95% | 4.07% | 34/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 45.86% | 2.85% | 0.09% | 41/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 45.82% | 5.36% | -6.91% | 29/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |